Abstract
In 2004, approximately 9 million people worldwide experienced a stroke, with the majority being ischemic in nature. While the prognosis for recovery can be good, long-term survival and functional outcome can be improved. Stroke survivors are at an increased risk for recurrent stroke and other ischemic vascular events and face significant cross-risk for atherothrombotic conditions affecting the coronary and peripheral vascular beds. As such, the secondary prevention of ischemic events in patients with stroke has focused on the treatment of atherosclerosis as a whole, with antiplatelet therapy playing a key role. There is some controversy regarding optimal antiplatelet therapy following stroke. The appropriate use of specific agents, the impact of stroke type and proper dosing, and other questions stem from an incomplete understanding of the issues, variability in clinical trial data, diversity in patient demographics, and differences in antiplatelet regimens. This review evaluates the clinical evidence for antiplatelet therapy in patients that have suffered an ischemic stroke, with an emphasis on balancing the benefits of a particular antiplatelet regimen with its attendant risk profile. The critical assessment of emerging trial data and its impact on existing treatment guidelines may aid in choosing the most appropriate antiplatelet regimen for comprehensive secondary prevention following stroke.
Keywords: Antiplatelet therapy, aspirin, clopidogrel, dipyridamole, ischemic stroke, secondary prevention, transient ischemic attack, atherosclerosis, cerebrovascular disease, hyperlipidemia
Current Vascular Pharmacology
Title: Antiplatelet Therapy for Secondary Prevention in Stroke – Making the Right Choice
Volume: 10 Issue: 2
Author(s): Geoffrey Ling
Affiliation:
Keywords: Antiplatelet therapy, aspirin, clopidogrel, dipyridamole, ischemic stroke, secondary prevention, transient ischemic attack, atherosclerosis, cerebrovascular disease, hyperlipidemia
Abstract: In 2004, approximately 9 million people worldwide experienced a stroke, with the majority being ischemic in nature. While the prognosis for recovery can be good, long-term survival and functional outcome can be improved. Stroke survivors are at an increased risk for recurrent stroke and other ischemic vascular events and face significant cross-risk for atherothrombotic conditions affecting the coronary and peripheral vascular beds. As such, the secondary prevention of ischemic events in patients with stroke has focused on the treatment of atherosclerosis as a whole, with antiplatelet therapy playing a key role. There is some controversy regarding optimal antiplatelet therapy following stroke. The appropriate use of specific agents, the impact of stroke type and proper dosing, and other questions stem from an incomplete understanding of the issues, variability in clinical trial data, diversity in patient demographics, and differences in antiplatelet regimens. This review evaluates the clinical evidence for antiplatelet therapy in patients that have suffered an ischemic stroke, with an emphasis on balancing the benefits of a particular antiplatelet regimen with its attendant risk profile. The critical assessment of emerging trial data and its impact on existing treatment guidelines may aid in choosing the most appropriate antiplatelet regimen for comprehensive secondary prevention following stroke.
Export Options
About this article
Cite this article as:
Ling Geoffrey, Antiplatelet Therapy for Secondary Prevention in Stroke – Making the Right Choice, Current Vascular Pharmacology 2012; 10 (2) . https://dx.doi.org/10.2174/157016112799305058
DOI https://dx.doi.org/10.2174/157016112799305058 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Physiological and Pathophysiological Role of Cysteine Metabolism in
Human Metabolic Syndrome
Drug Metabolism Letters Oxidative Stress and Nitric Oxide in Autism Spectrum Disorder and Other Neuropsychiatric Disorders
CNS & Neurological Disorders - Drug Targets Impaired Renal Autoregulation in Susceptible Models of Renal Disease
Current Vascular Pharmacology Targeted Metabolomics Reveals Hippurate as a Urinary Potential Marker for Diabetic Nephropathy
Current Metabolomics Medicinal Plants against Ischemic Stroke
Current Pharmaceutical Biotechnology Strategies to Create a Regenerating Environment for the Injured Spinal Cord
Current Pharmaceutical Design Current Directions in Non-Invasive Low Intensity Electric Brain Stimulation for Depressive Disorder
CNS & Neurological Disorders - Drug Targets Role of the Autonomic Nervous System in the Endothelial Dysfunction of the Metabolic Syndrome
Current Hypertension Reviews Osteoporosis Entwined with Cardiovascular Disease: The Implication of Osteoprotegerin and the Example of Statins
Current Medicinal Chemistry Caspase Function in Neuronal Death: Delineation of the Role of Caspases in Ischemia
Current Drug Targets - CNS & Neurological Disorders Resveratrol Protects β Amyloid-Induced Oxidative Damage and Memory Associated Proteins in H19-7 Hippocampal Neuronal Cells
Current Alzheimer Research Role of Grina/Nmdara1 in the Central Nervous System Diseases
Current Neuropharmacology Hot Melt Extruded and Injection Moulded Dosage Forms: Recent Research and Patents
Recent Patents on Drug Delivery & Formulation Natural Agents Modulating ACE-2: A Review of Compounds with Potential against SARS-CoV-2 Infections
Current Pharmaceutical Design Nutraceuticals as an Important Part of Combination Therapy in Dyslipidaemia
Current Pharmaceutical Design Biological Signatures of Disease in Neuro-Psychiatry as Inter-Theoretical Reduction
Current Topics in Medicinal Chemistry Diagnostic Value of 320-Slice Coronary CT Angiography in Coronary Artery Disease: A Systematic Review and Meta-Analysis
Current Medical Imaging Tumor Specific Imaging Using Tc-99m and Ga-68 Labeled Radiopharmaceuticals
Current Medical Imaging The Clinics and Etiology of Preeclampsia
Current Women`s Health Reviews Seaweed Proteins as a Source of Bioactive Peptides
Current Pharmaceutical Design